ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 59 filers reported holding ASCENDIS PHARMA A/S in Q3 2017. The put-call ratio across all filers is - and the average weighting 1.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $3,113,000 | -20.9% | 26,529 | +12.4% | 0.44% | +26.1% |
Q4 2020 | $3,936,000 | -21.8% | 23,599 | -27.6% | 0.35% | -29.4% |
Q3 2020 | $5,031,000 | -1.0% | 32,599 | -5.2% | 0.49% | +3.3% |
Q2 2020 | $5,084,000 | +38.6% | 34,373 | +5.5% | 0.48% | +4.1% |
Q1 2020 | $3,668,000 | -64.3% | 32,573 | -55.8% | 0.46% | -45.7% |
Q4 2019 | $10,263,000 | +44.4% | 73,773 | 0.0% | 0.85% | -23.0% |
Q3 2019 | $7,106,000 | -16.4% | 73,773 | 0.0% | 1.10% | -5.5% |
Q2 2019 | $8,495,000 | +5.7% | 73,773 | +8.1% | 1.16% | +58.5% |
Q1 2019 | $8,036,000 | +120.1% | 68,273 | +17.2% | 0.73% | +77.9% |
Q4 2018 | $3,651,000 | -44.4% | 58,273 | -37.1% | 0.41% | -45.4% |
Q3 2018 | $6,567,000 | +26.5% | 92,673 | +18.7% | 0.75% | +5.3% |
Q2 2018 | $5,192,000 | -16.8% | 78,048 | -18.3% | 0.72% | -24.5% |
Q1 2018 | $6,244,000 | +20.4% | 95,474 | -26.3% | 0.95% | +55.7% |
Q4 2017 | $5,187,000 | +10.5% | 129,474 | 0.0% | 0.61% | -9.1% |
Q3 2017 | $4,693,000 | +4.6% | 129,474 | -19.9% | 0.67% | -12.1% |
Q2 2017 | $4,486,000 | -37.3% | 161,617 | -36.7% | 0.76% | -45.5% |
Q1 2017 | $7,153,000 | +8.2% | 255,455 | -21.8% | 1.40% | -16.4% |
Q4 2016 | $6,611,000 | +24.8% | 326,622 | +24.0% | 1.67% | +94.1% |
Q3 2016 | $5,296,000 | +52.4% | 263,500 | +0.6% | 0.86% | -4.4% |
Q2 2016 | $3,474,000 | +185.9% | 261,800 | +274.0% | 0.90% | +615.9% |
Q1 2015 | $1,215,000 | – | 70,000 | – | 0.13% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management III, LLC | 133,691 | $13,805,000 | 36.44% |
RA Capital Management | 7,567,900 | $781,462,000 | 16.67% |
Q Global Advisors, LLC | 145,209 | $16,699,000 | 11.49% |
BERYLSON CAPITAL PARTNERS, LLC | 51,000 | $5,266,000 | 8.70% |
Spyglass Capital Management LLC | 949,915 | $98,088,000 | 6.94% |
Paradigm Biocapital Advisors LP | 497,347 | $51,356,000 | 6.85% |
Avoro Capital Advisors LLC | 2,850,000 | $294,291,000 | 5.44% |
Deep Track Capital, LP | 1,000,000 | $103,260,000 | 4.73% |
Finepoint Capital LP | 123,400 | $12,742,000 | 4.19% |
Deep Track Capital, LP | 800,000 | $82,608,000 | 3.78% |